 |
|
|
|
|
 |
Last Updated: Nov 1, 2009 - 11:48:48 PM |
Latest Research
:
Cancer
:
Blood
:
Multiple Myeloma
Predicting response of treatment in Multiple Myeloma patients
Researchers at Mayo Clinic Cancer Center, in cooperation with industry partners, have, for the first time, identified tumor specific alterations in the cellular pathway by which the multiple myeloma drug bortezomib (Velcade) works, and they have identified nine new genetic mutations in cancer cells that should increase a patient's chance of responding to the agent.The investigators say these findings, presented Sunday, Dec. 10, at the 2006 American Society of Hematology Annual Meeting in Orlando, may help physicians tailor treatment to patients with multiple myleoma, a difficult-to-treat cancer of plasma cells that is the second most common blood cancer in the United States.
Dec 10, 2006 - 12:50:17 PM
|
Latest Research
:
Cancer
:
Blood
:
Multiple Myeloma
Lenalidomide & dexamethasone combination shows promise for multiple myeloma treatment
Mayo Clinic Cancer Center investigators report that combination therapy with lenalidomide (RevlimidTM) and dexamethasone (combination is called Rev/Dex) looks like a breakthrough treatment for multiple myeloma. Results of a Phase II clinical trial were published online Aug. 23 in Blood.
Sep 4, 2005 - 7:15:38 AM
|
Latest Research
:
Cancer
:
Blood
:
Multiple Myeloma
Novel combination overcomes drug-resistant myeloma
A novel strategy devised by Dana-Farber Cancer Institute scientists has proved highly effective in killing drug-resistant multiple myeloma cells in the laboratory and could open a new form of attack on the deadly blood cancer, they report.
Jun 3, 2005 - 4:50:38 PM
|
Latest Research
:
Cancer
:
Blood
:
Multiple Myeloma
Bortezomib Based Therapies may Become the New Standard of Care in Multiple Myeloma
Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - News) today announced the presentation of positive clinical results for VELCADE in treating patients across the multiple myeloma (MM) treatment paradigm at the 10th Annual International Myeloma Workshop (IMW) in Sydney, Australia. Data regarding the use of VELCADE as a single agent and in combination with standard and emerging MM therapies were reported at the meeting.
Apr 14, 2005 - 8:56:38 PM
|
Latest Research
:
Cancer
:
Blood
:
Multiple Myeloma
FDA Fully Approves Bortezomib for Treatment of Relapsed and Refractory Multiple Myeloma
Millennium Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved the Company's supplemental New Drug Application (sNDA) for VELCADE(Bortezomib). This approval expands the label to include the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy.
Mar 26, 2005 - 10:01:38 AM
|
<< prev
next >>
|
|
|
|
